These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 34503154)

  • 1. Implementation of Multigene Germline and Parallel Somatic Genetic Testing in Epithelial Ovarian Cancer: SIGNPOST Study.
    Chandrasekaran D; Sobocan M; Blyuss O; Miller RE; Evans O; Crusz SM; Mills-Baldock T; Sun L; Hammond RFL; Gaba F; Jenkins LA; Ahmed M; Kumar A; Jeyarajah A; Lawrence AC; Brockbank E; Phadnis S; Quigley M; El Khouly F; Wuntakal R; Faruqi A; Trevisan G; Casey L; Burghel GJ; Schlecht H; Bulman M; Smith P; Bowers NL; Legood R; Lockley M; Wallace A; Singh N; Evans DG; Manchanda R
    Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness of Unselected Multigene Germline and Somatic Genetic Testing for Epithelial Ovarian Cancer.
    Manchanda R; Sun L; Sobocan M; Rodriguez IV; Wei X; Kalra A; Oxley S; Sideris M; Fierheller CT; Morgan RD; Chandrasekaran D; Rust K; Spiliopoulou P; Miller RE; Crusz SM; Lockley M; Singh N; Faruqi A; Casey L; Brockbank E; Phadnis S; Mills-Baldock T; El-Khouly F; Jenkins LA; Wallace A; Ahmed M; Kumar A; Swisher EM; Gourley C; Norquist BM; Evans DG; Legood R
    J Natl Compr Canc Netw; 2024 Apr; 22(2D):. PubMed ID: 38866043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age of ovarian cancer diagnosis among BRIP1, RAD51C, and RAD51D mutation carriers identified through multi-gene panel testing.
    Cummings S; Roman SS; Saam J; Bernhisel R; Brown K; Lancaster JM; Usha L
    J Ovarian Res; 2021 Apr; 14(1):61. PubMed ID: 33926482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Probability of detecting germline BRCA1/2 pathogenic variants in histological subtypes of ovarian carcinoma. A meta-analysis.
    Witjes VM; van Bommel MHD; Ligtenberg MJL; Vos JR; Mourits MJE; Ausems MGEM; de Hullu JA; Bosse T; Hoogerbrugge N
    Gynecol Oncol; 2022 Jan; 164(1):221-230. PubMed ID: 34702566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene Panel Tumor Testing in Ovarian Cancer Patients Significantly Increases the Yield of Clinically Actionable Germline Variants beyond
    Barbosa A; Pinto P; Peixoto A; Guerra J; Pinto C; Santos C; Pinheiro M; Escudeiro C; Bartosch C; Silva J; Teixeira MR
    Cancers (Basel); 2020 Sep; 12(10):. PubMed ID: 33008098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of BRCA Tumour Testing in an Integrated Molecular Tumour Board Multidisciplinary Model.
    Azzollini J; Vingiani A; Agnelli L; Tamborini E; Perrone F; Conca E; Capone I; Busico A; Peissel B; Rosina E; Ducceschi M; Mantiero M; Lopez S; Raspagliesi F; Niger M; Duca M; Damian S; Proto C; de Braud F; Pruneri G; Manoukian S
    Front Oncol; 2022; 12():857515. PubMed ID: 35463374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selecting Patients with Ovarian Cancer for Germline BRCA Mutation Testing: Findings from Guidelines and a Systematic Literature Review.
    Eccles DM; Balmaña J; Clune J; Ehlken B; Gohlke A; Hirst C; Potter D; Schroeder C; Tyczynski JE; Gomez Garcia EB
    Adv Ther; 2016 Feb; 33(2):129-50. PubMed ID: 26809252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883).
    Hauke J; Hahnen E; Schneider S; Reuss A; Richters L; Kommoss S; Heimbach A; Marmé F; Schmidt S; Prieske K; Gevensleben H; Burges A; Borde J; De Gregorio N; Nürnberg P; El-Balat A; Thiele H; Hilpert F; Altmüller J; Meier W; Dietrich D; Kimmig R; Schoemig-Markiefka B; Kast K; Braicu E; Baumann K; Jackisch C; Park-Simon TW; Ernst C; Hanker L; Pfisterer J; Schnelzer A; du Bois A; Schmutzler RK; Harter P
    J Med Genet; 2019 Sep; 56(9):574-580. PubMed ID: 30979843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond
    Fanale D; Incorvaia L; Filorizzo C; Bono M; Fiorino A; Calò V; Brando C; Corsini LR; Barraco N; Badalamenti G; Russo A; Bazan V
    Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32854451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes.
    Buys SS; Sandbach JF; Gammon A; Patel G; Kidd J; Brown KL; Sharma L; Saam J; Lancaster J; Daly MB
    Cancer; 2017 May; 123(10):1721-1730. PubMed ID: 28085182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Li-Fraumeni syndrome: not a straightforward diagnosis anymore-the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis.
    Batalini F; Peacock EG; Stobie L; Robertson A; Garber J; Weitzel JN; Tung NM
    Breast Cancer Res; 2019 Sep; 21(1):107. PubMed ID: 31533767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRIP1, RAD51C, and RAD51D mutations are associated with high susceptibility to ovarian cancer: mutation prevalence and precise risk estimates based on a pooled analysis of ~30,000 cases.
    Suszynska M; Ratajska M; Kozlowski P
    J Ovarian Res; 2020 May; 13(1):50. PubMed ID: 32359370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous germline and somatic sequencing in ovarian carcinoma: mutation rate and impact on clinical decision-making.
    Jorge S; McFaddin AS; Doll KM; Pennington KP; Norquist BM; Bennett RL; Pritchard CC; Swisher EM
    Gynecol Oncol; 2020 Mar; 156(3):517-522. PubMed ID: 31883735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of an educational and information systems initiative on somatic
    Fantoni A; Meniawy T; Cohen PA; McMullen M
    Gynecol Oncol Rep; 2023 Aug; 48():101246. PubMed ID: 37520785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Germline and Somatic
    You Y; Li L; Lu J; Wu H; Wang J; Gao J; Wu M; Liang Z
    Front Oncol; 2020; 10():295. PubMed ID: 32211327
    [No Abstract]   [Full Text] [Related]  

  • 16. Multigene Panel Germline Testing of 1333 Czech Patients with Ovarian Cancer.
    Lhotova K; Stolarova L; Zemankova P; Vocka M; Janatova M; Borecka M; Cerna M; Jelinkova S; Kral J; Volkova Z; Urbanova M; Kleiblova P; Machackova E; Foretova L; Hazova J; Vasickova P; Lhota F; Koudova M; Cerna L; Tavandzis S; Indrakova J; Hruskova L; Kosarova M; Vrtel R; Stranecky V; Kmoch S; Zikan M; Macurek L; Kleibl Z; Soukupova J
    Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32295079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutation Analysis of the RAD51C and RAD51D Genes in High-Risk Ovarian Cancer Patients and Families from the Czech Republic.
    Janatova M; Soukupova J; Stribrna J; Kleiblova P; Vocka M; Boudova P; Kleibl Z; Pohlreich P
    PLoS One; 2015; 10(6):e0127711. PubMed ID: 26057125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of pathogenic germline variants detected by multigene sequencing in unselected Japanese patients with ovarian cancer.
    Hirasawa A; Imoto I; Naruto T; Akahane T; Yamagami W; Nomura H; Masuda K; Susumu N; Tsuda H; Aoki D
    Oncotarget; 2017 Dec; 8(68):112258-112267. PubMed ID: 29348823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Significance of Germline Pathogenic Variants among 51 Cancer Predisposition Genes in an Unselected Cohort of Italian Pancreatic Cancer Patients.
    Puccini A; Ponzano M; Dalmasso B; Vanni I; Gandini A; Puglisi S; Borea R; Cremante M; Bruno W; Andreotti V; Allavena E; Martelli V; Catalano F; Grassi M; Iaia ML; Pirrone C; Pastorino A; Fornarini G; Sciallero S; Ghiorzo P; Pastorino L
    Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
    Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
    Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.